Taken together with these observations, our results demonstrate that the anti-breast cancer effects of DOT1L inhibition are mediated via modulation of a variety of biological processes, including growth and apoptosis signaling, EMT, CSC activity, and innate immune signaling. Here, DOT1L is linked to breast carcinoma.